Differential Analysis of Homocysteine and Uric Acid Levels in Patients with Cognitive Impairment Due to Parkinson’s Disease and Post-Stroke Conditions - Summary - MDSpire
Advertisement
Differential Analysis of Homocysteine and Uric Acid Levels in Patients with Cognitive Impairment Due to Parkinson’s Disease and Post-Stroke Conditions
To compare homocysteine (Hcy) and uric acid (UA) levels between patients with Parkinson’s disease with cognitive impairment (PD-CI) and those with post-stroke cognitive impairment (PS-CI), analyze the correlation of these biomarkers with cognitive function, and assess their heterogeneity across different disease types.
Key Findings:
PD-CI patients had significantly higher Hcy levels (mean difference: 2.55 μmol/L, 95% CI: 0.23–4.87, p = 0.032) and lower UA levels (mean difference: -34.66 μmol/L, 95% CI: -63.87 to -5.46, p = 0.020) compared to PS-CI patients.
Hcy levels negatively correlated with MMSE scores (r = -0.309, p = 0.001), stronger in PD-CI (r = -0.456, p < 0.001) than PS-CI (r = -0.175, p = 0.180).
UA levels showed no significant association with MMSE scores in either group.
Interpretation:
The findings indicate distinct metabolic profiles in PD-CI and PS-CI, with elevated Hcy consistently linked to cognitive impairment, while UA levels were specifically associated with PD-CI but not with cognitive impairment in either group.
Limitations:
Cross-sectional design limits causal inferences.
Findings require validation in larger, prospective studies.
Small sample size may affect generalizability.
Conclusion:
The study highlights the metabolic differences between PD-CI and PS-CI, suggesting that Hcy and UA may serve as potential biomarkers for differential diagnosis and understanding cognitive impairment mechanisms.
